Log in

Agios Pharmaceuticals Stock Forecast, Price & News

-1.18 (-2.54 %)
(As of 12/3/2020 12:00 AM ET)
Today's Range
Now: $45.25
50-Day Range
MA: $40.63
52-Week Range
Now: $45.25
Volume520,039 shs
Average Volume683,825 shs
Market Capitalization$3.13 billion
P/E RatioN/A
Dividend YieldN/A
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Agios Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.77 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AGIO



Sales & Book Value

Annual Sales$117.91 million
Book Value$6.94 per share


Net Income$-411,470,000.00
Net Margins-170.65%


Market Cap$3.13 billion
Next Earnings Date2/11/2021 (Estimated)
-1.18 (-2.54 %)
(As of 12/3/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

How has Agios Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AGIO stock has increased by 10.7% and is now trading at $45.25.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Agios Pharmaceuticals?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Agios Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Agios Pharmaceuticals?

Wall Street analysts have given Agios Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Agios Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Agios Pharmaceuticals

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its quarterly earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($1.43) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.36) by $0.07. The biopharmaceutical company earned $34.70 million during the quarter, compared to analysts' expectations of $38.12 million. Agios Pharmaceuticals had a negative return on equity of 57.63% and a negative net margin of 170.65%. The company's revenue was up 33.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.81) EPS.
View Agios Pharmaceuticals' earnings history

What price target have analysts set for AGIO?

12 Wall Street analysts have issued 12-month price targets for Agios Pharmaceuticals' stock. Their forecasts range from $49.00 to $82.00. On average, they expect Agios Pharmaceuticals' share price to reach $68.00 in the next year. This suggests a possible upside of 50.3% from the stock's current price.
View analysts' price targets for Agios Pharmaceuticals

Are investors shorting Agios Pharmaceuticals?

Agios Pharmaceuticals saw a decline in short interest in the month of October. As of October 30th, there was short interest totaling 6,070,000 shares, a decline of 16.6% from the October 15th total of 7,280,000 shares. Based on an average daily trading volume, of 689,600 shares, the short-interest ratio is presently 8.8 days.
View Agios Pharmaceuticals' Short Interest

Who are some of Agios Pharmaceuticals' key competitors?

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the following people:
  • Dr. Jacqualyn A. Fouse, CEO & Director (Age 59, Pay $1.25M)
  • Mr. Jonathan Biller J.D., CFO and Head of Legal & Corp. Affairs (Age 56, Pay $150.52k)
  • Dr. Scott A. Biller, Strategic Advisor (Age 64, Pay $687.56k)
  • Dr. Christopher J. Bowden, Chief Medical Officer (Age 59, Pay $701.63k)
  • Dr. Lewis Clayton Cantley, Co-Founder & Member of Scientific Advisory Board (Age 71)
  • Dr. Tak Wah Mak, Co-Founder & Member of Scientific Advisory Board (Age 74)
  • Dr. Craig B. Thompson, Co-Founder & Chairman of Scientific Advisory Board (Age 67)
  • Dr. Shin-San Su Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 64)
  • Ms. Carman Alenson, Principal Accounting Officer and VP of Accounting, Treasury & Tax
  • Dr. Clive Patience, Exec. VP of Technical Operations

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.94%), State Street Corp (2.99%), First Trust Advisors LP (2.61%), ArrowMark Colorado Holdings LLC (1.56%), Point72 Asset Management L.P. (0.69%) and Morgan Stanley (0.64%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, Jacqualyn A Fouse, Scott Biller and Steven L Hoerter.
View institutional ownership trends for Agios Pharmaceuticals

Which institutional investors are selling Agios Pharmaceuticals stock?

AGIO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., BNP Paribas Arbitrage SA, ExodusPoint Capital Management LP, Wells Fargo & Company MN, Equitable Holdings Inc., Peregrine Capital Management LLC, Charles Schwab Investment Management Inc., and Handelsbanken Fonder AB. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, and Christopher Bowden.
View insider buying and selling activity for Agios Pharmaceuticals

Which institutional investors are buying Agios Pharmaceuticals stock?

AGIO stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Candriam Luxembourg S.C.A., First Trust Advisors LP, State Street Corp, Point72 Asset Management L.P., Cubist Systematic Strategies LLC, Squarepoint Ops LLC, and AXA S.A.. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse.
View insider buying and selling activity for Agios Pharmaceuticals

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $45.25.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $3.13 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 536 workers across the globe.

What is Agios Pharmaceuticals' official website?

The official website for Agios Pharmaceuticals is www.agios.com.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.